LAVA Therapeutics NV
LVTX1.420USD
0.000
取引時間 （ET）15分遅れの株価
37.35M時価総額
損失額直近12ヶ月PER
詳細情報 LAVA Therapeutics NV 企業名
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
企業情報
企業コードLVTX
会社名LAVA Therapeutics NV
上場日Mar 25, 2021
最高経営責任者「CEO」Mr. Stephen A. Hurly
従業員数34
証券種類Ordinary Share
決算期末Mar 25
本社所在地Yalelaan 60
都市UTRECHT
証券取引所NASDAQ Global Select Consolidated
国Netherlands
郵便番号3584 CM
電話番号31630003035
ウェブサイトhttps://www.lavatherapeutics.com/
企業コードLVTX
上場日Mar 25, 2021
最高経営責任者「CEO」Mr. Stephen A. Hurly
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Hans Van Der Vliet, M.D., Ph.D.
Mr. Hans Van Der Vliet, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
77.35K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
30.00K
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Ms. Amy Garabedian
Ms. Amy Garabedian
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
8.85K
--
Ms. Nanna L. Lueneborg, Ph.D.
Ms. Nanna L. Lueneborg, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Dr. Guido Magni, M.D., Ph.D.
Dr. Guido Magni, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Stephen A. Hurly
Mr. Stephen A. Hurly
President, Chief Executive Officer, Management Director
President, Chief Executive Officer, Management Director
--
--
Mr. Joel Jean-Mairet, Ph.D.
Mr. Joel Jean-Mairet, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Benjamin Winograd, M.D., Ph.D.
Mr. Benjamin Winograd, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Paul W.H.I. Parren
Dr. Paul W.H.I. Parren
Executive Vice President Head of Research and Development
Executive Vice President Head of Research and Development
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Hans Van Der Vliet, M.D., Ph.D.
Mr. Hans Van Der Vliet, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
77.35K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
30.00K
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Ms. Amy Garabedian
Ms. Amy Garabedian
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
8.85K
--
Ms. Nanna L. Lueneborg, Ph.D.
Ms. Nanna L. Lueneborg, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Dr. Guido Magni, M.D., Ph.D.
Dr. Guido Magni, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Wed, Jun 4
更新時刻: Wed, Jun 4
株主統計
種類
株主統計
株主統計
比率
Cooperatieve Gilde Healthcare IV UA
20.61%
Versant Ventures
17.44%
Redmile Group, LLC
7.89%
BML Capital Management LLC
7.45%
Sanofi SA
7.30%
Other
39.31%
株主統計
株主統計
比率
Cooperatieve Gilde Healthcare IV UA
20.61%
Versant Ventures
17.44%
Redmile Group, LLC
7.89%
BML Capital Management LLC
7.45%
Sanofi SA
7.30%
Other
39.31%
種類
株主統計
比率
Corporation
32.27%
Venture Capital
17.53%
Investment Advisor
10.83%
Investment Advisor/Hedge Fund
7.95%
Hedge Fund
0.42%
Individual Investor
0.42%
Research Firm
0.22%
Other
30.35%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
48
18.32M
69.65%
-2.73M
2025Q1
59
22.25M
84.60%
-1.27M
2024Q4
61
18.80M
71.50%
-11.80K
2024Q3
56
15.93M
60.60%
-3.34M
2024Q2
58
16.07M
61.13%
-4.19M
2024Q1
58
16.06M
61.10%
-4.38M
2023Q4
51
18.10M
68.85%
+283.15K
2023Q3
52
18.00M
68.48%
-418.56K
2023Q2
55
18.03M
68.58%
-1.16M
2023Q1
60
19.21M
73.06%
-886.64K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Cooperatieve Gilde Healthcare IV UA
5.42M
20.61%
--
--
Mar 31, 2025
Versant Ventures
4.59M
17.44%
--
--
Mar 31, 2025
Redmile Group, LLC
2.07M
7.89%
--
--
Mar 31, 2025
BML Capital Management LLC
1.96M
7.45%
+2.50K
+0.13%
Mar 31, 2025
Sanofi SA
1.92M
7.3%
+1.92M
--
Dec 31, 2024
Merck & Co Inc
1.15M
4.37%
--
--
Mar 31, 2025
Bruce & Company, Inc.
521.87K
1.98%
-250.00K
-32.39%
Mar 31, 2025
Zenito Oy
156.83K
0.6%
--
--
Mar 31, 2025
Pathway Financial Advisors, LLC
102.50K
0.39%
--
--
Mar 31, 2025
Powell (Fred M)
65.00K
0.25%
-7.56K
-10.42%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
AltShares Event-Driven ETF
0%
AltShares Event-Driven ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
